Age-Specific Normal Ranges for Alpha-Fetoprotein (AFP)
Serum AFP reference intervals vary substantially by age because AFP physiologically declines after birth. [1]
Lab-specific reference intervals should be used for clinical interpretation. [2]
Two commonly used age-stratified reference interval sets are listed below (units: ng/mL). [1], [2]
Age-Stratified Reference Intervals (Selected Reference Sets)
Childrens Hospital of Philadelphia (CHOP) PLM Laboratory reference ranges (AFP ng/mL) [1]
- 0–30 days: Male 0.6–16,387; Female 0.6–18,964. [1]
- 1–11 months: Male 0.6–28.3; Female 0.6–77.0. [1]
- 1–3 years: Male 0.6–7.9; Female 0.6–11.1. [1]
- 4–6 years: Male 0.6–5.6; Female 0.6–4.2. [1]
- 7–12 years: Male 0.6–3.7; Female 0.6–5.6. [1]
- 13–20 years: Male 0.6–3.9; Female 0.6–4.2. [1]
- ≥21 years: Male 0.0–8.9; Female 0.0–8.9. [1]
Labcorp AFP (tumor marker) reference ranges (AFP ng/mL; nonpregnant females) [2]
- 0–7 days: 0.0–75,265.8 (male and female). [2]
- 8–30 days: 0.0–32,556.4 (male and female). [2]
- 1 month: Male 0.0–1,747.8; Female 0.0–1,600.3. [2]
- 2 months: Male 0.0–391.1; Female 0.0–550.0. [2]
- 3 months: Male 0.0–225.8; Female 0.0–339.9. [2]
- 4 months: Male 0.0–230.6; Female 0.0–230.6. [2]
- 5 months: Male 0.0–118.0; Female 0.0–234.0. [2]
- 6 months: Male 0.0–97.2; Female 0.0–97.2. [2]
- 7–11 months: 0.0–60.3 (male and female). [2]
- 1 year: 0.0–21.4 (male and female). [2]
- 2 years: Male 0.0–9.4; Female 0.0–10.1. [2]
- 3–4 years: Male/Female 0.0–5.5. [2]
- 5 years: Male 0.0–3.6; Female 0.0–4.2. [2]
- 6–12 years: Male/Female 0.0–3.9. [2]
- 13–17 years: Male/Female 0.0–4.3. [2]
- 18–30 years: Male 0.0–5.7; Female 0.0–4.7. [2]
- 31–50 years: Male 0.0–6.9; Female 0.0–6.4. [2]
- 51–80 years: Male 0.0–8.4; Female 0.0–9.2. [2]
- >80 years: Male 0.0–6.4; Female 0.0–8.7. [2]
Evaluation Principles for Elevated AFP
Elevated AFP requires confirmation that the result is clinically interpretable for the patient’s sex, pregnancy status, and assay method. [2]
Values across different assay methodologies should not be compared for serial interpretation. [2]
Normal AFP reference interpretation applies only to males and nonpregnant females. [2]
Measurement Reconfirmation and Context Assessment
AFP should be interpreted using the laboratory’s age-appropriate reference interval. [2]
Serial interpretation should use a single assay method when monitoring clinical course. [2]
A pregnancy history should be documented because interpretation guidance excludes pregnant females. [2]
Etiologic Patterns That Drive the Evaluation Pathway
Hepatocellular carcinoma (HCC) can present with elevated AFP, but a substantial proportion of HCC has normal AFP. [3]
AFP is also elevated in other malignancies and benign liver conditions. [3], [4]
Hepatic (HCC-Directed) Evaluation Components
AFP should be assessed in the context of underlying liver disease and imaging. [3]
AASLD guidance notes that AFP at a threshold of 400 ng/mL was previously used as a diagnostic criterion for HCC. [3]
AASLD guidance states that over 40% of HCC can have normal AFP levels. [3]
AASLD guidance also notes that elevated AFP can occur in other cancers including intrahepatic cholangiocarcinoma, gastric cancer, and germ cell tumors. [3]
Germ Cell (Testicular/Extragonadal) Evaluation Components
Elevated AFP may reflect germ cell tumors in appropriate clinical contexts. [4]
The AUA testicular cancer guideline lists multiple non-malignant sources of AFP, including liver disease and hereditary persistence of AFP (HPAFP). [4]
Non-malignant and benign causes should be considered before treatment decisions based solely on AFP magnitude. [4]
Monitored Marker Elevation Versus Urgent Diagnostic Escalation
Treatment decisions based only on “elevated” AFP values that are stable and below 25 ng/mL are discouraged in the AUA testicular cancer guideline. [4]
When tumor markers and imaging are equivocal, repeat imaging at 6–8 weeks may be used to clarify extent of disease in the AUA testicular cancer guideline. [5]
Common Pitfalls to Avoid
AFP assay results across different methodologies should not be compared for serial trending. [2]
Interpretation should not be applied to pregnant patients using nonpregnant reference intervals. [2]
AFP should not be treated as disease-specific for HCC because substantial proportions of HCC have normal AFP and elevated AFP can be seen in other cancers and benign liver disease. [3], [4]
Treatment-Independent Diagnostic Goal: Confirm or Exclude Malignancy and Identify Reversible Benign Causes
The evaluation should integrate AFP magnitude, age, pregnancy status, liver disease risk, other laboratory findings, and diagnostic imaging to determine the underlying cause. [3], [4]
For suspected malignancy, diagnostic staging and tissue diagnosis pathways should follow established cancer-specific guidance rather than AFP levels alone. [3], [5]
Targets and Goals of Therapy for Elevated AFP
No universal AFP treatment target exists for all etiologies because AFP is a marker with disease-specific interpretation. [3]
Cancer-specific targets rely on disease response assessment and marker kinetics within condition-specific management frameworks. [5]